CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.
Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是一种细胞癌症免疫疗法,与传统治疗相比,已显著改善血液系统恶性肿瘤的治疗结局。然而,许多患者未能获得持久应答。非线性混合效应建模可整合现有知识,在具有定量性且受生理机制指导的框架中,帮助深入理解CAR-T 细胞疗法独特但尚未充分阐明的剂量-暴露和暴露-应答关系。
不过,要充分发挥其潜力,需要信息量充足且高效的临床数据收集研究设计。本研究旨在基于已发表的CAR-T 细胞动力学和肿瘤动态机制模型,开发最佳实验设计框架,为稳健且可行的CAR-T 临床研究设计提供依据。考虑研究人群差异和参数不确定性后,我们:(1)确定估计模型参数所需的最小人群规模;(2)评估不同采样策略;(3)提出灵活采样时间窗,以取代固定时间点。优化后的研究设计包括60例患者、3个固定肿瘤负荷评估时间点(第0、30和90天),以及3个可行CAR-T 采样时间窗(输注后第2–4、12–18和32–47天)。随机模拟和参数估计显示,与固定采样时间点设计相比,采用采样时间窗的优化设计在估计模型参数方面表现更好,包括刻画异质性结局的参数,证实其效率和稳健性。该框架有望促进未来以可行且节约资源的方式收集CAR-T 临床数据,并展示最佳实验设计如何推动复杂癌症免疫疗法在临床试验和临床实践中的开发与优化。
CAR-T cell therapy is a cellular cancer immunotherapy that has impressively improved outcomes in hematological malignancies compared to conventional treatments. Yet, many patients do not respond permanently. Nonlinear mixed-effects modeling can support a better understanding of the unique and not fully understood dose-exposure and exposure-response relationships for CAR-T cell therapy by integrating available knowledge into a quantitative, physiology-motivated framework.
However, to unfold its full potential, it requires informative and efficient study designs for clinical data collection.
We aimed to develop an optimal experimental design framework informing a robust and feasible clinical CAR-T cell study design based on a published mechanistic model of CAR-T cell kinetics and tumor dynamics. By considering variability between study populations and parameter uncertainty, we (1) identified the minimal population size required to inform model parameters, (2) assessed different sampling strategies, and (3) informed flexible sampling windows instead of fixed sampling timepoints. The optimized study design consisted of 60 patients, three fixed assessments of tumor burden (days 0, 30 and 90), and three feasible CAR-T cell sampling windows (days 2-4, 12-18 and 32-47 after infusion).
In stochastic simulation and estimation, the optimized design with sampling windows showed better performance in informing model parameters, including those characterizing heterogeneous outcomes, than designs with fixed sampling timepoints, confirming its efficiency and robustness.
This framework shall facilitate future feasible and resource-efficient CAR-T cell clinical data collection, thus showcasing the potential of optimal experimental design to advance the development and optimization of complex cancer immunotherapies in clinical trials and clinical practice.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。